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Obstructive Sleep Apnea 
in Heart Failure:
Review of Prevalence, Treatment with 
Continuous Positive Airway Pressure, and Prognosis
Obstructive sleep apnea is a sleep-related breathing disorder that has a major impact on 
cardiovascular function. It has been associated with hypertension, coronary artery dis-
ease, cardiac arrhythmias, sudden cardiac death, and heart failure. This review focuses on 
the relationship between obstructive sleep apnea and heart failure with either reduced or 
preserved ejection fraction. We discuss the pathophysiology of obstructive sleep apnea, 
as well as its prevalence, treatment outcomes with continuous positive airway pressure, 
and prognosis in these 2 distinct types of heart failure. We also identify areas in which 
further work is needed to improve our understanding of this association in heart failure 
patients. (Tex Heart Inst J 2018;45(3):151-61)
H eart failure (HF), which affects approximately 23 million people worldwide
1 
and 5.8 million in the United States, has created a substantial healthcare 
burden.2 The incidence and prevalence of HF are increasing in the U.S., 
mainly because of an aging population and the ability to prolong cardiac patients’ lives 
by means of innovative therapies.2 Many factors contribute to the development and 
progression of HF; one of these is obstructive sleep apnea (OSA). The prevalence of 
OSA is substantially higher in patients who have HF with reduced ejection fraction 
(HFrEF) or HF with preserved ejection fraction (HFpEF) than in the general popula-
tion. In this literature review, we explore the relationship between OSA and these 2 
types of HF and provide perspective on the pathophysiologic and clinical significance 
of these associations.
Sleep Apnea
Sleep apnea is characterized by partial or complete cessation of breathing during night-
time sleep, resulting in repeated arousal from sleep, oxyhemoglobin desaturation, and 
daytime sleepiness. Apnea is defined as complete cessation of airf low for >10 s (Table 
I).3 Hypopnea, a partial cessation of airf low, is defined as a 50% to 90% reduction 
in airf low for >10 s, accompanied by a >3% decrease in oxyhemoglobin saturation 
(Sao2) and terminated by electroencephalographic arousal.
4 The 3 types of apnea 
are central, obstructive, and mixed. Central sleep apnea (CSA) is characterized by a 
complete withdrawal of central respiratory drive to the inspiratory muscles, includ-
ing the diaphragm, and results in the simultaneous absence of naso-oral airf low and 
thoracoabdominal excursions. In OSA, the thoracic inspiratory muscles, including the 
diaphragm, are active, so thoracoabdominal excursions are seen. Absence of airf low 
results from upper-airway occlusion caused by lost pharyngeal dilator muscle tone, 
with consequent pharyngeal collapse. Mixed apnea has an initial central component 
followed by an obstructive component. Like apnea, hypopnea can also be obstructive 
or central. We focus here on obstructive causes.
 Although OSA is also called obstructive sleep apnea-hypopnea syndrome,5 we use 
the term OSA as defined by the American Academy of Sleep Medicine Task Force, 
in which 5 or more episodes of apnea or hypopnea occur per hour of sleep (apnea-
hypopnea index [AHI]). Clinically, OSA can present as daytime sleepiness or loud 
snoring, witnessed apneas, arousal due to gasping or choking, impaired concentration 
or memory, morning headaches, mood disorders, or insomnia.4 Obstructive sleep 
apnea is classified as mild (AHI, 5–14), moderate (AHI, 15–30), or severe (AHI, >30). 
Attended overnight polysomnography in a sleep laboratory is accepted as the best di-
agnostic test for measuring AHI. Portable cardiorespiratory monitoring devices have 
Review
Himad K. Khattak, MD
Faisal Hayat, MD
Salpy V. Pamboukian, MD
Harvey S. Hahn, MD
Brian P. Schwartz, MD
Phyllis K. Stein, PhD





py; prevalence; risk factors; 
sleep apnea syndromes/
classification/physiopatholo-





From: Department of Car-
diology (Drs. Hahn, Khattak, 
and Schwartz), Kettering 
Medical Center, Kettering, 
Ohio 45420; Department 
of Cardiology (Dr. Hayat), 
Marshall University, Hun-
tington, West Virginia 25701; 
Division of Cardiovascular 
Disease (Dr. Pamboukian), 
University of Alabama at 
Birmingham, Birmingham, 
Alabama 35233; and Cardio-
vascular Division (Dr. Stein), 
Washington University in St. 
Louis, St. Louis, Missouri 
63110
Address for reprints: 
Himad K. Khattak, MD, 
Kettering Medical Center, 
3535 Southern Blvd., 
Kettering, OH 45429
E-mail: himadk@yahoo.com
152      Obstructive Sleep Apnea in Heart Failure June 2018, Vol. 45, No. 3
also been developed for in-home screening and diagno-
sis of OSA. However, despite the advantages of conve-
nience, lower cost, and patient acceptance, they measure 
fewer physiologic variables than does polysomnography. 
In-home polysomnographic results have not been me-
ticulously validated and are not considered adequate to 
guide therapy, particularly in the HF population.
Obstructive Sleep Apnea 
in the General Population
In the general population, OSA affects approximately 
4% of middle-aged men and 2% of middle-aged 
women.6 The lower prevalence of OSA in women is 
not well understood, although female hormones may 
play a role.7,8 In the Wisconsin Sleep Cohort Study,6 
a population-based prospective study of cardiopul-
monary disorders of sleep in 3,513 participants, the 
estimated prevalence of undiagnosed sleep apnea was 
9% in women and 24% in men. In other studies,8-14 
population-prevalence estimates for mild and moderate 
OSA range from 3% to 28% and 1% to 14%, respec-
tively. On the basis of average prevalence, an estimated 
1 in 5 adults has at least mild OSA and 1 in 15 has at 
least moderate OSA.7 Data from the Sleep Heart Health 
Study,15 in which investigators examined cross-sectional 
relationships between sleep-related breathing disor-
ders and self-reported cardiovascular disease in 6,424 
adults, showed that OSA is associated with a 2.38 rela-
tive odds of having HF. The results of several studies 
in HF populations show a diverse overall prevalence of 
obstructive and central sleep-related breathing disorders 
(range, 47%–81%), probably attributable to different 
demographic criteria (age, sex, ethnicity, and race), risk 
factors (obesity and comorbid conditions), AHI cutoff, 
and severity of HF in the different populations.
Pathophysiologic Consequences of 
Obstructive Sleep Apnea and Heart Failure
Obstructive sleep apnea is characterized by recurrent 
pharyngeal collapse during sleep. Patients generally have 
a narrow, highly compliant pharynx that is prone to 
collapse upon normal withdrawal of pharyngeal dilator 
muscle tone during sleep, thus enabling airway narrow-
ing (hypopnea) or occlusion (apnea). Many patients are 
obese, and fat deposition around the pharynx may be 
partly responsible for pharyngeal narrowing.16 Evidence 
suggests that rostral displacement of f luid that has accu-
mulated in the legs during the day causes edema of the 
peripharyngeal structures when lying asleep, predispos-
ing the individual to OSA.17-20
 Obstructive sleep apnea is deleterious to the cardio-
vascular system through mechanical, chemical, neuro-
humoral, and inf lammatory mechanisms (Fig. 1).21 The 
immediate effects of an attempted inspiratory effort 
during an episode of mechanical obstruction to airf low 
include an exaggerated drop in intrathoracic pressure, 
hypoxia, and arousal. The drop in intrathoracic pres-
sure increases left ventricular (LV) transmural pressure, 
which increases afterload; this drop in pressure increases 
venous return, causing right ventricular distention and a 
leftward shift of the interventricular septum and conse-
quent decreased LV filling.22 The net result of decreased 
LV filling and increased afterload is reduced stroke vol-
ume. Obstructive sleep apnea also causes marked and 
repeated elevations in systemic blood pressure (BP) sec-
ondary to hypoxia, arousals from sleep, and increased 
sympathetic nervous system activity (SNA). The SNA 
is furthered by the decreased stroke volume, by sup-
pression of the sympathetic inhibitory effects of lung 
stretch receptors by apnea, or both. The combination of 
increased LV afterload and faster heart rate secondary 
to augmented SNA leads to myocardial oxygen supply/
demand mismatch, acutely predisposing the patient to 
cardiac ischemia and arrhythmias, and chronically to 
LV hypertrophy, LV enlargement, and HF.
TABLE I. Terminology Used in Sleep-Disordered  
Breathing3
Apnea 
Cessation of airflow for >10 s
Hypopnea  
A reduction in but not complete cessation of airflow to <50% 
of normal, usually in association with a >3% reduction in 
oxyhemoglobin saturation, lasting >10 s
Apnea-Hypopnea Index (AHI) 
The frequency of apnea and hypopnea events per hour of sleep; 
a measure of the severity of sleep apnea
Arousal 
Transient awakening from sleep, lasting <10 s
Epworth Sleepiness Scale (ESS) 
Subjectively measures sleepiness during routine daily activities 
and is often used as a screening test for detecting excessive 
sleepiness
NREM (non-rapid eye movement) sleep 
Quiet sleep
REM (rapid eye movement) sleep 
Active sleep; associated with skeletal muscle atonia and 
dreaming
Oxygen desaturation 
Reduction in oxyhemoglobin saturation, usually consequent to 
apnea or hypopnea
Polysomnography 
Multiparametric electrophysiologic recording of 
electroencephalographic, electroculographic, electromyographic, 
electrocardiographic, and respiratory activity to identify sleep-
related breathing disturbances
Thoracoabdominal excursions 
Measured qualitatively by respiratory inductance 
plethysmography or by pneumatic respiration transducers 
placed over the ribcage and abdomen
 
Adapted with permission from Chowdhury M, et al., J Card Fail 
2010;16(2):164-74.3
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 Except for rapid-eye-movement (REM) sleep, which 
generally constitutes 20% to 25% of sleep and is associ-
ated with short surges of sympathetic activity, sleep gen-
erally is a period of increased vagal activity that results 
in slower heart rates and lower BPs. Conversely, arousals 
after disordered breathing events in OSA increase SNA 
and most likely the risk of HF development or progres-
sion.23
 Hypoxemia with resultant systolic24-28 or diastolic29 
dysfunction may also diminish oxygen delivery to the 
myocardium. Risks include myocardial ischemia, ar-
rhythmias, and sudden cardiac death during sleep 
from the generation of free oxygen radicals and in-
f lammation. Patients with OSA have low plasma nitrite 
concentrations and diminished endothelial-mediated va-
sodilation.30 Reactive oxygen species selectively activate 
inf lammatory pathways by activating nuclear factor-
kappa B (NFκB) rather than hypoxia-inducible factor-1 
(HIF-1), the transcriptional regulator of the adaptive 
pathway.31 Activation of NFκB leads to increased pro-
duction of tumor necrosis factor-α, interleukin-6, in-
terleukin-8, and C-reactive protein, as well as adhesion 
molecules such as intracellular and vascular cell adhe-
sion molecules, E selectin, and CD15,32 that can lead to 
endothelial damage, atherogenesis, and HF. Infiltrating 
inf lammatory cells activate profibrotic transforming 
growth factor-β, which leads to increased deposition of 
extracellular matrix and consequent myocardial fibro-
sis,33 and to worsening LV diastolic function.
Prevalence of Obstructive Sleep Apnea in 
Heart Failure with Reduced Ejection Fraction
Polysomnographic34-39 and polygraphic study results40-42 
have shown a higher prevalence of sleep-disordered 
breathing (SDB) (47%–81%) and OSA (12%–53%) 
in HFrEF patients than in the general population (Fig. 
2).43 Table II34-42 summarizes prevalence studies of OSA 
in HFrEF patients3; most patients were male, and mean 
ages were similar. Mean body mass index (BMI) was 
below 30 in all studies. The inclusion criteria varied 
from AHI ≥5 to ≥15, and did or did not include patients 
with CSA. The relative proportion of patients with 
OSA or CSA tended to be highest in the studies that 
categorized patients as having OSA at AHI ≥5; regard-
less, significant OSA is prevalent in HFrEF patients.
 Older age,34,35,39-42 male sex,34 higher BMI,34,36-38 and 
habitual snoring36,38 are major risk factors for OSA in 
patients with HFrEF, just as in the general population.6 
However, OSA patients with HFrEF have less subjective 
daytime sleepiness despite shorter sleep times, and the 
Fig. 1  Diagram shows pathophysiologic mechanisms by which obstructive sleep apnea affects cardiovascular function and heart 
failure. Modified with permission from Mann DL. Heart failure: a companion to Braunwald’s heart disease. Philadelphia: Elsevier; 2011. 
p. 484.21 
 
BP = blood pressure; HF = heart failure; HR = heart rate; LV = left ventricular; LVH = left ventricular hypertrophy; PNA = parasympa-
thetic nervous system activity; RV = right ventricular; RVH = right ventricular hypertrophy; SNA = sympathetic nervous system activity; 
SV = stroke volume; VR = venous return
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Epworth Sleepiness Scale (ESS) is not helpful in iden-
tifying OSA in this population.34,39,44 Moreover, atrial 
f ibrillation,34,36-40,42 ventricular arrhythmias,36,38 lower 
LV ejection fraction (LVEF),36,38,39,42 and higher levels 
of serum brain natriuretic peptide (BNP),35,41 endothe-
lin-1,35 and urinary norepinephrine39 have been reported 
as predictors of risk for SDB and particularly CSA in 
HFrEF.
Prevalence of Obstructive Sleep Apnea in 
Heart Failure with Preserved Ejection Fraction
The prevalence of diastolic dysfunction has been stud-
ied echocardiographically in OSA patients who have no 
history of HF (Table III).45-47 Fung and colleagues45 used 
transmitral valve pulsed-wave Doppler echocardiogra-
phy to f ind diastolic dysfunction (grade I) in 37% of 
patients with newly diagnosed OSA. When comparing 
patients with an AHI >40 versus <40, the authors re-
ported an association between severe SDB and a higher 
degree of diastolic dysfunction evidenced by prolonged 
isovolumetric relaxation time (IVRT), although, of 
note, this AHI cutpoint of 40 identified severely affect-
ed patients. Other authors reported abnormal diastolic 
function (with use of tissue-Doppler echocardiography) 
and an increased left atrial volume index in obese but 
otherwise healthy patients with OSA in comparison 
with similarly obese patients without OSA.46 Finally, 























Javaheri S, et al.38 (1998)a 81 100 63 28 0.25 75 >15 I–III 44b 11 40
Sin DD, et al.37 (1999) 450 85 60b 29b 0.27b 66 >15 II–IV 37.6b 32 29
Ferrier K, et al.40 (2005) 53 77 60.1 28 0.34 NR >10 I–IV 31b 53 15
Javaheri S, et al.36 (2006)a 100 100 65 NR 0.24b 69 >15 I–III 44b 12 37
Oldenburg O, et al.42 (2007) 700 80 64.5b 27 0.283 46 >5 II–IV 24.7b 36 40
Schulz R, et al.39 (2007) 203 75 65.3 27.6 0.28 57 >10 II–III 34b 43 28
Vazir A, et al.35 (2007) 55 100 61 29.4 0.306 53 > or ≥15c II 27b 15 38
Yumino D, et al.34 (2009) 218 77 55.6 29.2 0.25d 40 >15 II–IV NR 26 21
Herrscher T, et al.41 (2011)e 71 85 61.4 28.4 0.296 73 >5 II–IV NR 49 32
 
AHI = Apnea-Hypopnea Index; BMI = body mass index; CSA = central sleep apnea; ICM = ischemic cardiomyopathy; LVEF = left 
ventricular ejection fraction; NYHA = New York Heart Association; NR = not reported; OSA = obstructive sleep apnea; Pts = patients; 




a Significant difference between patients with and without SDB. 
b Overlap of patients between 2 trials. 
c Source article variably states >15 and ≥15. 
d Data exclude CSA patients. 
e Data exclude patients with heart failure with preserved ejection fraction. 
 
All studies were prospective except Sin DD, et al.37 (retrospective). 
 
Table adapted from Chowdhury M, et al. J Card Fail 2010;16(2):164-74.3 Used with permission.
Fig. 2  Graph shows prevalence of obstructive sleep apnea 
(OSA) in studies of patients with heart failure and reduced ejec-
tion fraction. Authors used Apnea-Hypopnea Index (AHI) cutoffs 
of ≥15 events/hr (Yumino D, et al.34; Vazir A,* et al.35; Javaheri 
S, et al.36; and Sin DD, et al.37), ≥10 events/hr (Ferrier K, et al.40; 
and Schulz R, et al.39), and ≥5 events/hr (Herrscher T, et al.41; and 
Oldenburg O, et al.42). Unattended overnight cardiorespiratory 
polygraphy was used in hospital 39,42 and home41 sleep studies; 
otherwise, overnight-attended polysomnography was used. One 
study was retrospective37; the others were prospective. Because 
of patient overlap between 2 studies,36,38 one38 is not included 
here. 
 
Figure adapted with permission from Kasai T, Bradley TD. J Am 
Coll Cardiol 2011;57(2):119-27.43 
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diastolic dysfunction was more prevalent in moderate-
to-severe OSA than in mild or no OSA.47
 Data on the prevalence of SDB in patients with 
HFpEF are sparse (Table IV).41,48,49 Chan and col-
leagues48 found signif icant SDB in 11 of 20 patients 
and used prolonged deceleration time to show that 
those with SDB had worse diastolic dysfunction. In a 
study of 244 patients with HFpEF, Bitter and associ-
ates49 estimated that 69% had SDB (40% had OSA 
and 29% CSA). The proportion of patients with SDB, 
particularly CSA, increased as did diastolic dysfunction, 
suggesting that CSA acts as a marker of HFpEF sever-
ity, as in HFrEF.42 In addition, older age, worse New 
York Heart Association (NYHA) functional class, obe-
sity, and higher levels of N-terminal pro-BNP were as-
sociated with both types of SDB. Diabetes mellitus and 
higher BMI were predictors of OSA. When Herrscher 
and colleagues41 studied a population similar to that 
of Bitter and associates in terms of age, sex, NYHA 
class, and the use of HF medications, the prevalence of 
OSA was 64%. Higher BMI was significantly associ-
ated with OSA. However, in these studies,41,49 SDB was 
evaluated by using unattended overnight cardiorespi-
ratory polygraphy; only Chan and colleagues’ patients 
underwent overnight-attended polysomnography.48
CPAP in Patients with Heart Failure and 
Reduced Ejection Fraction
In a study of the effects of continuous positive airway 
pressure (CPAP) in 8 patients with OSA and HFrEF,50 
oxygen desaturation, systolic BP, heart rate, and intra-
thoracic pressure decreased during stage 2 non-REM 
TABLE III. Prevalence Studies* of Diastolic Dysfunction in Patients with OSA and No History of Heart Failure
 Pts Male Mean Age  BMI   
     Reference (n) (%) (yr) Characteristics (kg/m2) AHI** Findings
Fung JW, et al.45 68 90 48.1 Newly diagnosed OSA 28.5 ≥5 DD in 37% pts; 
(2002)       more severe OSA 
       associated with worse 
       DD (longer IVRT)
Sidana J, et al.47 20 30 45 Obese, pregastric bypass; 49 vs 48 <5 Moderate-to-severe 
(2005)    12 pts with and 8 without  >5–14 OSA associated with 
    OSA  ≥15 higher prevalence of 
       moderate-to-severe DD
Otto ME, et al.46 41 100 45 Obese; 23 pts with 33.7 vs 32.3 ≥15 vs <5 Increased left atrial 
(2007)    and 18 without OSA   volume index and 
       DD in OSA pts vs 
       non-OSA pts
 
AHI = Apnea-Hypopnea Index; BMI = body mass index; DD = diastolic dysfunction; IVRT = isovolumetric relaxation time;  
OSA = obstructive sleep apnea; Pts = patients 
 
  *With use of echocardiography 
**Events/hr
TABLE IV. Prevalence Studies of Sleep-Disordered Breathing in Patients with Heart Failure 
and Preserved Ejection Fraction


















(%)Mean OSA No SDB
Chan J, et al.48 
(1997)
20 65 65 28 29.1a 27.6 >0.50 >10 II–III 35 20
Bitter T, et al.49 
(2009)
244 64 65 NR 29.3b 26.4 >0.55 ≥5 II–IV 40 29
Herrscher T, et al.41 
(2011)c
44 71 62.8 30.4 32b 27.9 0.517 >5 II–IV 64 18
 
AHI = Apnea-Hypopnea Index; BMI = body mass index; CSA = central sleep apnea; LVEF = left ventricular ejection fraction; NR = not 




a Patients with SDB (includes OSA and CSA) 
b OSA versus no SDB, P <0.05 
c Data exclude patients with systolic heart failure.
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sleep. Nocturnal CPAP has also been shown to reduce 
central sympathetic vasoconstrictor outf low51 and im-
prove vagal modulation of the heart by increasing high-
frequency heart rate variability.52
 Investigators have conducted randomized clinical 
investigations (Table V)43,53-56 into the effects of noc-
turnal CPAP in patients with HFrEF and OSA. In 
a monthlong study of 24 patients, Kaneko and col-
leagues53 found significant reductions in AHI, number 
of arousals per night, and daytime systolic BP and heart 
rate in conjunction with a decrease in LV end-systolic 
diameter and an 8.8% absolute increase in LVEF on 
2-dimensional echocardiograms. This study had no pla-
cebo group; however, the same measurement in the un-
treated control group did not improve, which suggests 
that a sustained reduction in LV afterload secondary to 
CPAP therapy was the reason for improved LVEF in the 
treated group. This study included equal numbers of pa-
tients with ischemic and nonischemic cardiomyopathy.
 Previously, the same group of authors,57 in an uncon-
trolled study of 8 patients with OSA and nonischemic 
dilated cardiomyopathy, reported a 12% increase in 
LVEF after one month of CPAP therapy. Upon with-
drawal of CPAP for one week, LVEF worsened, strongly 
suggesting that CPAP had reversed OSA. Mansfield 
and co-authors,54 in a randomized trial of 40 patients, 
reported that 3 months of CPAP treatment resulted in 
a signif icant absolute increase of 5% in LVEF. How-
ever, no decrease in BP was reported; the authors at-
tributed this result to optimal vasodilator therapy that 
may have diminished the benef icial effects of CPAP 
on BP. The improved LVEF was related to a decrease 
in SNA, as evidenced by a 42% decrease in overnight 
urinary norepinephrine levels.54 The modestly improved 
LVEF, as compared with that reported by Kaneko 
and colleagues,53 can be attributed to less severe OSA 
(AHI, 26 vs 42) and higher baseline LVEF (0.35 vs 
0.28). There were also signif icant reductions in AHI 
and improvement in subjective sleepiness measured by 
the ESS. Smith and associates,55 in a placebo-controlled 
crossover trial of autotitrating CPAP in 23 patients 
with HFrEF and OSA, reported modest improvement 
in subjective sleepiness, but none in other subjective or 
objective criteria of HF severity, including LVEF. This 
was notable, because these patients had baseline LVEF 
and OSA severity similar to Kaneko and colleagues’ pa-
tients.53 Autotitrating CPAP has reduced AHI and ESS 
scores as has fixed CPAP; however, the relative efficacy 
of auto-CPAP versus clinically titrated CPAP remains 
unclear.58,59 Compliance with CPAP was poorer55 (3.5 
hr/night) than that reported by Kaneko53 (6.2 hr/night) 
and Mansfield54 (5.6 hr/night), and its efficacy was not 
tested by using follow-up polysomnography. Therefore, 
lower compliance with CPAP and thus its poorer ef-
ficacy might explain the absence of cardiovascular ben-
efits.
 In a randomized, multicenter, placebo-controlled trial 
of CPAP therapy in 45 OSA patients with HFrEF,56 



















Baseline Changes with CPAP Use
AHI* LVEF ESS AHI* LVEF ESS
SBP 
(mmHg)
Kaneko Y, Control 12 55.2 10 32.3 — — 45.2 0.285 5.7 –0.5 0.15 NA   6
et al.53 (2003) CPAP 12 55.9 11 30.4 1 6.2 37.1 0.25 6.8 –28.8a 0.88a NA –10a
Mansfield DR, Control 21 57.5 18 34.6 — — 26 0.336 8.8 –8.4 0.15 11 –6
et al.54 (2004) CPAP 19 57.2 19 33.5 3 5.6 25 0.376 9.5 –21.1a 0.50a –3.1a   1
Smith LA, Sham ACPAP 23 61 20 31 — — 36 0.29 10 NA 0.10 –2 NA
et al.55 (2007) ACPAP — — — — 1.5 3.5 — — — — 0.10 –3b NA
Egea CJ, Sham CPAP 25 64 23 30.5 — — 35 0.272 6.9  –7.3 –0.05 –1.7 –1.6
et al.56 (2008)c CPAP 20 63 19 31.7 3 NR 44 0.288 8.6 –32.9a   0.22a –3.6 0
 
ACPAP = auto-titrating continuous positive airway pressure; AHI = Apnea-Hypopnea Index; avg = average; BMI = body mass index; 
CPAP = continuous positive airway pressure; ESS = Epworth Sleepiness Scale; LVEF = left ventricular ejection fraction; NA = not 





aP <0.01 for comparison between groups 
bP <0.05 for comparison between groups 
cInvestigators studied patients with SDB, including both OSA and CSA; data shown here, except for AHI, are for patients with OSA. 
 
Studies were randomized clinical trials; one55 included double-crossover. 
 
Adapted with permission from Kasai T, Bradley TD. J Am Coll Cardiol 2011;57(2):119-27.43
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LVEF improved by an absolute 2.2% in the treatment 
group. Even greater improvement in patients with base-
line LVEF >0.30 suggests that myocardial contractile 
reserve is a marker of LVEF improvement. Follow-up 
polysomnography proved the efficacy of CPAP by re-
vealing significantly reduced AHI in patients who had 
CSA and OSA.
 Investigators in a nonrandomized trial of patients 
with HFrEF60 compared the effects of acute and chronic 
CPAP therapy on LV systolic and diastolic functions 
in 7 patients with OSA and 5 without OSA. Stroke 
volume and LVEF were reduced in acute CPAP admin-
istration, whereas 7 weeks of chronic CPAP resulted in 
improved stroke volume and an absolute increase of 5% 
in LVEF. Neither therapy affected diastolic function or 
LV filling pressures. The improved stroke volume and 
LVEF from chronic CPAP therapy was directly related 
to the systemic vascular resistance index. Similarly, in an 
observational study to evaluate the effects of 6 months 
of CPAP therapy on HFrEF and OSA, Ferrier and as-
sociates61 compared 19 patients treated with CPAP and 
7 untreated patients. With CPAP therapy, improvement 
occurred in LVEF (4.7% absolute increase), systolic BP, 
and sleepiness, but not in exercise levels, BNP, or sym-
pathetic activity as measured by urinary norepinephrine 
levels and heart rate. The modest increase in LVEF as 
compared with that found by Kaneko and colleagues53 
was attributed to lower compliance with CPAP (4.2 vs 
6.2 hr/night) and less severe baseline systolic dysfunc-
tion (mean LVEF, 0.35 vs 0.28).
 On the basis of the observations in the random-
ized (Table V)43,53-56 and nonrandomized clinical trials 
of CPAP treatment in OSA and HFrEF, we concur 
with the conclusions of Kasai and co-authors52 that 
f ixed-pressure CPAP reduces sympathetic activ-
ity,50,53,54 BP,50,52,60 and ESS scores,54,55,61 and improves 
LVEF.53,54,56,60,61 Improved quality of life was noted in 
patients with baseline ESS scores >10,54 but not in those 
with scores <10.56,61 Autotitrating CPAP failed to im-
prove LVEF.52
CPAP in Patients with 
Heart Failure with Preserved Ejection Fraction
Investigators have examined the effects of CPAP ther-
apy on LV diastolic function in patients with OSA but 
without HFpEF. In a randomized, placebo-controlled, 
double-blinded crossover study,62 diastolic function 
improved in these patients after 12 weeks of CPAP 
therapy. Conventional echocardiography showed im-
proved function through significantly reduced IVRT 
and deceleration time as well as an increase in the ratio 
of peak early filling velocity (E) to peak late filling ve-
locity (A) of diastolic transmitral f low (E/A). Other 
authors63 compared 15 patients who had moderate-to-
severe OSA and no comorbidities with normal obese 
persons and reported significantly decreased diastolic 
BP and improved diastolic dysfunction (increased E/A 
ratio, decreased IVRT) after 3 months of CPAP ther-
apy. Cloward and colleagues64 reported regression of 
LV hypertrophy in 25 patients with severe OSA after 
6 months of nasal CPAP therapy. In another study,65 
although LVEF was conserved, the authors reported 
significantly reduced LV wall thickness (interventricu-
lar septum and LV posterior wall) and improved global 
function after 6 months of CPAP therapy in patients 
with severe OSA. Shivalkar and associates66 studied pa-
tients with OSA and no concomitant cardiopulmonary 
disease who had 6 months of CPAP therapy and found 
that their symptoms, hemodynamic status, and ven-
tricular structure and function significantly improved. 
Diastolic velocities improved significantly in younger 
patients and variably in older patients.66 In another 
study,67 tissue-Doppler images showed improved systolic 
and diastolic function after 6 months of CPAP therapy 
in patients with newly diagnosed OSA.
 We are unaware of randomized or nonrandomized 
clinical trials of the effects of chronic CPAP therapy in 
patients with OSA and HFpEF. The only report of dia-
stolic function in patients with OSA and HFpEF after 
CPAP therapy noted no changes in relevant echocar-
diographic indices.60 However, this study lasted only 7 
weeks, so longer therapy may be necessary to determine 
whether CPAP has beneficial effects on diastolic func-
tion, as reported in the studies of patients with OSA and 
no history of HFpEF (3–6 mo).62-67
Effects of CPAP on Morbidity and Mortality 
Rates in Heart Failure with Reduced Ejection 
Fraction
In a study of HF patients undergoing evaluation for heart 
transplantation, Roebuck and colleagues68 monitored 22 
patients with OSA and 23 patients without OSA for a 
median duration of 52 months. Results of CPAP’s effi-
cacy were inconclusive, because no distinction was made 
between treated and untreated OSA. Few investigators 
have researched the effects of CPAP on mortality rates 
in OSA patients with HFrEF (Table VI).69,70 Wang and 
associates69 prospectively recruited 164 patients with 
HFrEF, categorized them into 3 groups (mild to no sleep 
apnea, untreated OSA, and OSA treated with CPAP), 
and monitored them for a median duration of >7 years. 
After control for confounding variables, the mortality 
rate was significantly higher among the group of 37 pa-
tients with untreated moderate-to-severe OSA than in 
the group with mild to no sleep apnea. The 14 patients 
treated with CPAP had slightly better survival prospects 
than did the untreated patients (P=0.07). The study was 
limited by small sample size, nonrandomization, higher 
baseline AHI in the treatment group, and unavailable 
data on CPAP compliance; a large-scale, randomized 
trial might confirm better survival rates in HFrEF pa-
tients whose OSA is treated.
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 Kasai and colleagues70 classif ied 88 patients with 
moderate-to-severe OSA into a CPAP-treated group 
(n=65) and an untreated group (n=23). The CPAP 
group was subdivided into 2 groups: more compli-
ant (n=32; average nightly CPAP use, 6 hr) and less 
compliant (n=33; average nightly CPAP use, 3.5 hr). 
After a mean duration of 2.1 years, increased risk of 
death and hospitalization was found in the untreated 
(P=0.03) and less compliant (P=0.01) groups. Because 
of the small sample size and the 39% first-month drop-
out rate among untreated patients, these findings need 
to be confirmed by results from a larger study.
 Jilek and co-authors,71 in an observational study of 
273 patients with HFrEF, concluded that SDB was as-
sociated with higher mortality rates and positive airway 
pressure was associated with improved prognosis. The 
study compared mortality rates in patients with severe 
SDB versus none to moderate SDB; however, only 22% 
of patients in the severe-SDB group had predominant 
OSA, so the results did not confirm that CPAP would 
lower mortality rates in patients with HFrEF.
 In an observational study of 384 patients with HFrEF 
(62% had OSA), Damy and coworkers72 reported a 
poor prognosis after a mean follow-up period of 47 ± 
25 months in patients whose OSA had improved with 
use of nocturnal ventilation therapy (CPAP with bilevel 
positive airway pressure and adaptive seroventilation). 
Because of the nonrandomized nature of this study, the 
cutoff of 20 events/hr for treatment, and the different 
ventilation modes, we think that these f indings need 
confirmation by a larger and randomized trial in which 
patients receive treatment on the basis of the most recent 
recommendations. Khayat and colleagues, who had 
suggested a role for OSA in acute decompensation of 
HF,73 later found that severe OSA (AHI, >30) indepen-
dently predicted 6-month cardiac hospital readmissions 
in patients with HFrEF. However, this does not show 
that CPAP treatment would necessarily be effective.74
Remaining Questions and Challenges
We found no studies in which the effects of CPAP on 
mortality rates in patients with OSA and HFpEF were 
examined. Further research is needed.
 Obstructive sleep apnea contributes substantially to 
the development and progression of HF. In patients 
with HFrEF and HFpEF, OSA is more prevalent than 
in the general population. However, the effects of CPAP 
on HF progression and mortality rates have been stud-
ied only in OSA patients who have HFrEF. Promising 
echocardiographic studies have been conducted into 
the effect of CPAP on diastolic dysfunction in patients 
with OSA. In addition, despite considerable advances 
in managing OSA in HFrEF, minimal progress has 
been made in managing OSA in HFpEF. Therefore, 
randomized clinical trials are certainly needed to evalu-
ate the effects of CPAP on HF progression and survival 
prospects in HFpEF patients with OSA.
 Furthermore, excessive daytime sleepiness caused by 
repeated arousals at night is characteristic of OSA in pa-
tients without HF. Patients with OSA and HF have less 
subjective daytime sleepiness despite less sleep time, and 
the ESS is unhelpful in predicting OSA in this popula-
tion.34,39,41,44 Although fixed-pressure CPAP reduces ESS 
scores in HFrEF patients,54,55,61 it improves quality of life 
only when baseline ESS scores are >10.54
 These observations illuminate 3 important ques-
tions regarding the relationship between OSA and HF. 
First, which HF patients need a screening sleep study 
TABLE VI. Observational Studies of Effects of CPAP Treatment on Long-Term Outcomes in Patients with OSA and 



















Wang H, et al.69 
(2007)
M-NSA 113 66 53.5 29 0.255 6.9 — 2.9/7.3 Higher mortality rate in 
untreated group vs M-NSA 
group; tendency toward 
decreased mortality rate in 
treated vs untreated group 
(P=0.07)
Untreated 37 87 58.5 30.1 0.259 32.8 —
Treated 14 100 53.2 32.3* 0.239 38.8 NR
Kasai T, et al.70 
(2008)
Untreated 23 83 59.8 24.9 0.35 38.2 — 2.1/4.8 Increased risk of death and 
hospitalization in untreated 
group (P=0.03) and less 
compliant CPAP-treated group 
(P=0.01)
Treated 65 95 59.6 27.5** 0.362 45.1 4.9
 
AHI = Apnea-Hypopnea Index; avg = average; BMI = body mass index; CPAP = continuous positive airway pressure; LVEF = left 
ventricular ejection fraction; Max. = maximum; M-NSA = mild to no sleep apnea; NR = not reported; OSA = obstructive sleep apnea; 
Pts = patients 
 
  *P <0.05 for comparison with M-NSA 
**P <0.05 for comparison between groups 
 
Adapted with permission from Kasai T, Bradley TD. J Am Coll Cardiol 2011;57(2):119-27.43
Texas Heart Institute Journal Obstructive Sleep Apnea in Heart Failure      159
when the ESS is unreliable for screening? Schulz and 
colleagues40 recommended sleep studies in all HFrEF 
patients with LVEF <0.40; however, this idea has not 
been generally accepted, because of uncertainty about 
whether and how to treat OSA in this population and 
the need for treatment goals.75 Currently, because of no 
guidelines, the indications for sleep studies to evaluate 
OSA in patients without HF apply equally to patients 
with HF: obesity, habitual snoring, witnessed apnea, 
unrefreshing sleep, excessive daytime sleepiness, and 
hypertension.
 Second, subjective excessive daytime sleepiness may 
be absent in patients with OSA and HF, so do they need 
CPAP treatment? This question applies even to patients 
with OSA and no evidence of HF. The observations by 
Wang 69 and Kasai70 support CPAP in patients with HF, 
regardless of daytime symptoms. However, the need for 
large-scale, highly powered clinical trials is apparent.
 Third, the ESS is unreliable in HF patients, so there 
is a need for a new sleepiness scale that can better pre-
dict the risk of OSA in these patients. Poor quality of 
life in HF might be why sleepiness is not perceived as a 
predominant symptom; the new sleepiness scale should 
take quality of life into consideration.
 Because patients with HFpEF and OSA share clini-
cal profiles, it may not be surprising if a large study 
were to show that OSA is more prevalent in HFpEF 
than in HFrEF, a finding noted in the only small-scale 
study that included both HFpEF and HFrEF patients.41 
For these reasons, we think that further elucidation of 
the role of OSA and OSA treatment in patients with 
HFpEF is needed.
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